MANNKIND CORP Interest Expense
MANNKIND CORP (MNKD) reported Interest Expense of $6.05 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-07.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-08-07
- MANNKIND CORP interest expense for the quarter ending 2024-06-30 was $6.05M, a 11.96% decline year-over-year.
- MANNKIND CORP interest expense for the quarter ending 2024-03-31 was $2.57M, a 7.86% decline year-over-year.
- MANNKIND CORP interest expense for the quarter ending 2023-12-31 was $2.68M, a 4.70% decline year-over-year.
- MANNKIND CORP interest expense for the quarter ending 2023-09-30 was $2.81M, a 0.11% increase year-over-year.
- MANNKIND CORP interest expense for fiscal 2023 was $15.15M, a 0.93% increase from fiscal 2022.
- MANNKIND CORP interest expense for fiscal 2022 was $15.01M, a 1.27% decline from fiscal 2021.
- MANNKIND CORP interest expense for fiscal 2021 was $15.20M.
- MANNKIND CORP interest expense for fiscal 2015 was $24.10M, a 18.14% increase from fiscal 2014.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2024-06-30 | $6.05M 10-Q · filed 2024-08-07 | $8.62M 10-Q · filed 2024-08-07 | $11.29M derived: sum of 3 quarters · filed 2024-08-07 | $14.11M derived: sum of 4 quarters · filed 2024-08-07 | |||
| 2024-03-31 | $2.57M 10-Q · filed 2024-05-08 | $5.24M derived: sum of 2 quarters · filed 2024-05-08 | $8.06M derived: sum of 3 quarters · filed 2024-05-08 | $14.93M derived: sum of 4 quarters · filed 2024-08-07 | |||
| 2023-12-31 | $2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $5.49M derived: sum of 2 quarters · filed 2024-02-27 | $12.37M derived: sum of 3 quarters · filed 2024-08-07 | $15.15M 10-K · filed 2024-02-27 | |||
| 2023-09-30 | $2.81M 10-Q · filed 2023-11-07 | $9.69M derived: sum of 2 quarters · filed 2024-08-07 | $12.47M 10-Q · filed 2023-11-07 | $15.28M derived: sum of 4 quarters · filed 2024-08-07 | |||
| 2023-06-30 | $6.87M 10-Q · filed 2024-08-07 | $9.66M 10-Q · filed 2024-08-07 | $12.47M derived: sum of 3 quarters · filed 2024-08-07 | $15.28M derived: sum of 4 quarters · filed 2024-08-07 | |||
| 2023-03-31 | $2.79M 10-Q · filed 2024-05-08 | $2.42M 10-Q · filed 2023-05-09 | $5.59M derived: sum of 2 quarters · filed 2024-05-08 | $8.41M derived: sum of 3 quarters · filed 2024-05-08 | $15.05M derived: sum of 4 quarters · filed 2024-05-08 | ||
| 2022-12-31 | $2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $5.62M derived: sum of 2 quarters · filed 2024-02-27 | $12.26M derived: sum of 3 quarters · filed 2024-02-27 | $15.01M 10-K · filed 2024-02-27 | $9.55M 10-K · filed 2023-02-23 | ||
| 2022-09-30 | $2.81M 10-Q · filed 2023-11-07 | $9.45M derived: sum of 2 quarters · filed 2023-11-07 | $12.20M 10-Q · filed 2023-11-07 | $7.13M 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $6.64M 10-Q · filed 2023-08-07 | $9.39M 10-Q · filed 2023-08-07 | |||||
| 2022-03-31 | $2.37M 10-Q · filed 2023-05-09 | ||||||
| 2021-12-31 | $15.20M 10-K · filed 2024-02-27 | $1.37M 10-K · filed 2023-02-23 | |||||
| 2015-12-31 | $24.10M 10-K · filed 2016-03-15 | ||||||
| 2014-12-31 | $20.40M 10-K · filed 2016-03-15 | ||||||
| 2013-12-31 | $21.50M 10-K · filed 2016-03-15 | ||||||
| 2012-12-31 | $21.60M 10-K · filed 2015-03-02 | ||||||
| 2011-12-31 | $21.80M 10-K · filed 2014-03-03 | ||||||
| 2010-12-31 | $17.40M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |